33 results
8-K
ALPN
Alpine Immune Sciences Inc
21 Dec 23
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
4:23pm
to provide AbbVie with a data package based on the Analysis and including certain information described in the Amendment (the “Revised Data Package … ”). AbbVie may exercise the Option until its expiration 90 days following the date the Company delivers to AbbVie the Revised Data Package, subject
8-K
ALPN
Alpine Immune Sciences Inc
18 Jun 20
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101
8:04am
”). The Option is immediately exercisable and will expire 90 days following the delivery by the Company of the Option Exercise Data Package (as defined below … the Development Plan providing for, among other things, the generation of a data package in order for AbbVie to evaluate exercising the Option (the “Option
8-K
EX-10.2
wb5jrm
1 Apr 19
Departure of Directors or Certain Officers
4:16pm
10-Q
EX-10.1
xfv5dqt
4 Aug 15
Quarterly report
12:00am
8-K
EX-99.1
j7659 5n3
21 Dec 23
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
4:23pm
424B5
osjoy j7pylcba65kc
7 Nov 23
Prospectus supplement for primary offering
8:15pm
424B5
q8zs g1sq0i3hb
6 Nov 23
Prospectus supplement for primary offering
6:05am